Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: Final 48-week clinical and virologic outcomes

Journal of Infectious Diseases

Volumn 199, Issue 6, 2009, Pages 866-871

  Wilkin, Timothy J ^a,m   McKinnon, John E ^c   DiRienzo, A Gregory ^b   Mollan, Katie ^e   Fletcher, Courtney V ^g   Margolis, David M ^h   Bastow, Barbara ⁱ   Thal, Gary ^l   Woodward, William ^d   Godfrey, Catherine ^j   Wiegand, Ann ^k   Maldarelli, Frank ^k   Palmer, Sarah ^k   Coffin, John M ^f   Mellors, John W ^c   Swindells, Susan ^g  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d Abbott Laboratories   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f TUFTS UNIVERSITY   (United States)

^g UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

^l BRISTOL MYERS SQUIBB   (United States)

^m Ground Floor ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; RITONAVIR; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; GENE SEQUENCE; GENOME ANALYSIS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAINTENANCE THERAPY; MALE; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEINASE INHIBITION; SIDE EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VIREMIA;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PILOT PROJECTS; PYRIDINES; RITONAVIR; TREATMENT OUTCOME; VIREMIA; YOUNG ADULT;

EID: 65649151755     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/597119     Document Type: Article

References (21)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: November 3, 2008. Department of Health and Human Services. 2008. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 21 January 2009.
2. Kahlert C, Hupfer M, Wagels T, et al. Ritonavir boosted indinavir treatment as a simplified maintenance "mono"-therapy for HIV infection. AIDS 2004; 18:955-7.
3. Pierone G Jr, Mieras J, Bulgin-Coleman D, et al. A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy. HIV Clin Trials 2006; 7:237-45.
4. Vernazza P, Daneel S, Schiffer V, et al. The role of compartment penetration in PI-monotherapy: the atazanavir-ritonavir monomaintenance (ATARITMO) trial. AIDS 2007; 21:1309-15.
5. Nunez EP, Oliveira MS, Almeida MMTB, et al. 48 week efficacy and safety results of simplification to single agent lopinavir/ritonavir (LPV/r) regimen in patients suppressed below 80 copies/ml on HAART-the KalMO study [abstract]. In: Program and abstracts of the XVI international AIDS conference (Toronto). Geneva: International AIDS Society, 2008.
6. Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22:F1-9.
7. Cameron DW, da Silva BA, Arribas JR, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavirritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008; 198:234 - 40.
8. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48- week results. Clin Infect Dis 2007; 44:1484-92.
9. Wood R, Phanuphak P, Cahn P, et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 2004; 36: 684-92.
10. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296:806-14.
11. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12:255-66.
12. Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatmentexperienced patients are missed by standard genotype analysis. J Clin Microbiol 2005; 43:406-13.
13. Stanford resistance database. Available at: http://hivdb.stanford.edu/.
14. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: spring 2008. Top HIV Med 2008; 16:62-8.
15. Palmer S, Wiegand AP, Maldarelli F, et al. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41:4531-6.
16. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008; 105:3879-84.
17. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-61.
18. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296:769-81.
19. McKinnon JE, Arribas JR, Pulido F, Delgado R, Mellors JW. The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. AIDS 2006; 20:2331-5.
20. Karlstrom O, Josephson F, Sonnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr 2007; 44:417-22.
21. Schackman BR, Scott CA, Sax PE, et al. Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis 2007; 45:1062-70.